Mark Lewis: The ‘trolley problem’ of adjuvant chemotherapy in colon cancer

Mark Lewis shared a post on X, about paper published in Journal of Clinical Oncology:

Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?

Authors: Lars A. Pahlman, Werner M. Hohenberger, Klaus Matzel, Kenichi Sugihara, Philip Quirke and Bengt Glimelius.

”Every time I grapple with the ‘trolley problem’ of adjuvant chemotherapy in colon cancer, I return to this manuscript (written in 2016 in Journal of Clinical Oncology and thus preceding many ctDNA-informed approaches but also foretelling the top-heavy risk/benefit of oxaliplatin).”

Source: Mark Lewis/X

Mark Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer. His interests are neuroendocrine tumors and cancer syndromes.